Jonas Lanz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jonas Lanz has a total of 379 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Pilgrim
Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
50 shared publications - Stefan Stortecky
Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
41 shared publications - Stephan Windecker
Department of Cardiology Inselspital, University Hospital Bern, University of Bern Bern Switzerland
28 shared publications Stephan Windecker
From the Departments of Cardiology (B.B., Z.L., S.D., C.D., J.S., H.G., L.A., G.S., M.B.B., J.L., T.P., S.W., S.S., C.G.) and Nuclear Medicine (F.C., A.R.), Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, CH-3010 Bern, Switzerland
27 shared publicationsDik Heg
Department of Clinical Research, University of Bern , Bern
23 shared publications- Fabien Praz
Department of Cardiology, Bern University Hospital, Bern, Switzerland
20 shared publications
Latest Publications
- Top Cited Papers
- 2 November 2025
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 67 (11)
Reply to Garcia-Villarreal et al. concerning the 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease
- 2 November 2025
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 67 (11)
Top Cited PapersReply to Garcia-Villarreal et al. concerning the 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease
- 23 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 1 (1)
2025 ESC/EACTS Guidelines for the management of valvular heart disease
- 23 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 1 (1)
2025 ESC/EACTS Guidelines for the management of valvular heart disease
- Top Cited Papers
- 29 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (44) , 4635-4736
2025 ESC/EACTS Guidelines for the management of valvular heart disease
- 29 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (44) , 4635-4736
Top Cited Papers2025 ESC/EACTS Guidelines for the management of valvular heart disease
- Top Cited Papers
- 2 August 2025
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 67 (8)
2025 ESC/EACTS Guidelines for the management of valvular heart disease
- 2 August 2025
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 67 (8)
Top Cited Papers2025 ESC/EACTS Guidelines for the management of valvular heart disease
- Open Access
- 6 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (9) , e035916
Clinical Outcomes in Patients With Acute Pulmonary Embolism Undergoing Ultrasound‐Assisted Catheter‐Directed Thrombolysis
Background: Ultrasound‐assisted catheter‐directed thrombolysis (USAT) for acute pulmonary embolism (PE) has garnered specific interest and is commonly employed in intermediate‐risk PE to prevent cardiac decompensation and death. However, evidence supporting the effectiveness and safety of USAT in routine clinical practice is limited. We therefore aimed to investigate the safety and effectiveness of USAT in a large patient population with PE. Methods and Results: The ERASE PE (Bern Acute Pulmonary Embolism Registry) is a single‐center cohort study investigating the safety and effectiveness of PE treatment according to the decision of the local PE response team. The specified primary outcome was in‐hospital mortality. Between October 2017 and April 2023, 315 patients (mean age 64.3±14.2 years; 38% female) with intermediate‐high (n=257, 82%) and high risk (n=58, 18%) PE were treated with USAT. Patients presented with tachycardia (heart rate 104.3±20.4 bpm), hypoxemia (peripheral oxygen saturation 89.2%±7.5%), elevated mean pulmonary artery pressures (30.7±8.0 mm Hg), and reduced mixed venous saturation (venous oxygen saturation 58.5%±10.2%). Patients received USAT with a cumulative dose of 19.8±6.6mg rt‐PA over 14.4±2.2 hours. USAT was effective in reducing right ventricular overload and pulmonary artery pressure in 88% of patients with a mean reduction of right ventricular/left ventricular ratio of 0.37±0.29 and mean pulmonary artery pressure of 8.5±7.7 mm Hg, respectively. The primary end point was observed in 10 patients (3.2%). One patient had an embolic stroke (0.3%), 25 patients (7.9%) exhibited bleeding, including 3 patients with intracranial hemorrhage (1.0%), and 3 patients (1.0%) had recurrent PE. Conclusions: Among patients with acute PE, USAT effectively reduces right ventricular overload and mean pulmonary artery pressure with low rates of in‐hospital mortality and bleeding. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04355975.
- 6 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (9) , e035916
Open AccessClinical Outcomes in Patients With Acute Pulmonary Embolism Undergoing Ultrasound‐Assisted Catheter‐Directed Thrombolysis
Background: Ultrasound‐assisted catheter‐directed thrombolysis (USAT) for acute pulmonary embolism (PE) has garnered specific interest and is commonly employed in intermediate‐risk PE to prevent cardiac decompensation and death. However, evidence supporting the effectiveness and safety of USAT in routine clinical practice is limited. We therefore aimed to investigate the safety and effectiveness of USAT in a large patient population with PE. Methods and Results: The ERASE PE (Bern Acute Pulmonary Embolism Registry) is a single‐center cohort study investigating the safety and effectiveness of PE treatment according to the decision of the local PE response team. The specified primary outcome was in‐hospital mortality. Between October 2017 and April 2023, 315 patients (mean age 64.3±14.2 years; 38% female) with intermediate‐high (n=257, 82%) and high risk (n=58, 18%) PE were treated with USAT. Patients presented with tachycardia (heart rate 104.3±20.4 bpm), hypoxemia (peripheral oxygen saturation 89.2%±7.5%), elevated mean pulmonary artery pressures (30.7±8.0 mm Hg), and reduced mixed venous saturation (venous oxygen saturation 58.5%±10.2%). Patients received USAT with a cumulative dose of 19.8±6.6mg rt‐PA over 14.4±2.2 hours. USAT was effective in reducing right ventricular overload and pulmonary artery pressure in 88% of patients with a mean reduction of right ventricular/left ventricular ratio of 0.37±0.29 and mean pulmonary artery pressure of 8.5±7.7 mm Hg, respectively. The primary end point was observed in 10 patients (3.2%). One patient had an embolic stroke (0.3%), 25 patients (7.9%) exhibited bleeding, including 3 patients with intracranial hemorrhage (1.0%), and 3 patients (1.0%) had recurrent PE. Conclusions: Among patients with acute PE, USAT effectively reduces right ventricular overload and mean pulmonary artery pressure with low rates of in‐hospital mortality and bleeding. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04355975.
- 17 December 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (25) , 2046-2069
Aortic Stenosis and Coronary Artery Disease: Decision-Making Between Surgical and Transcatheter Management
Aortic stenosis (AS) and coronary artery disease (CAD) frequently coexist and share pathophysiological mechanisms. The proportion of patients with AS and CAD requiring revascularization varies widely because of uncertainty about best clinical practices. Although combined surgical aortic valve replacement and coronary artery bypass grafting has been the standard of care, management options in patients with AS and CAD requiring revascularization have expanded with the advent of transcatheter aortic valve replacement (TAVR). Potential alternative treatment pathways include revascularization before TAVR, concomitant TAVR and percutaneous coronary intervention, percutaneous coronary intervention after TAVR and deferred percutaneous coronary intervention or hybrid procedures. Selection depends on underlying disease severity, antithrombotic treatment strategies, clinical presentation, and symptom evolution after TAVR. In patients undergoing surgical aortic valve replacement, the addition of coronary artery bypass grafting has been associated with improved long-term mortality, especially if CAD is complex. although it is associated with higher periprocedural risk. The therapeutic impact of percutaneous coronary intervention in patients with TAVR is less well-established. The multitude of clinical permutations and remaining uncertainties do not support a uniform treatment strategy for patients with AS and CAD. Therefore, to provide the best possible care for each individual patient, heart teams need to be familiar with the available data on AS and CAD. Herein, we provide an in-depth review of the evidence supporting the decision-making process between transcatheter and surgical approaches and the key elements of treatment selection in patients with AS and CAD.
- 17 December 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (25) , 2046-2069
Aortic Stenosis and Coronary Artery Disease: Decision-Making Between Surgical and Transcatheter Management
Aortic stenosis (AS) and coronary artery disease (CAD) frequently coexist and share pathophysiological mechanisms. The proportion of patients with AS and CAD requiring revascularization varies widely because of uncertainty about best clinical practices. Although combined surgical aortic valve replacement and coronary artery bypass grafting has been the standard of care, management options in patients with AS and CAD requiring revascularization have expanded with the advent of transcatheter aortic valve replacement (TAVR). Potential alternative treatment pathways include revascularization before TAVR, concomitant TAVR and percutaneous coronary intervention, percutaneous coronary intervention after TAVR and deferred percutaneous coronary intervention or hybrid procedures. Selection depends on underlying disease severity, antithrombotic treatment strategies, clinical presentation, and symptom evolution after TAVR. In patients undergoing surgical aortic valve replacement, the addition of coronary artery bypass grafting has been associated with improved long-term mortality, especially if CAD is complex. although it is associated with higher periprocedural risk. The therapeutic impact of percutaneous coronary intervention in patients with TAVR is less well-established. The multitude of clinical permutations and remaining uncertainties do not support a uniform treatment strategy for patients with AS and CAD. Therefore, to provide the best possible care for each individual patient, heart teams need to be familiar with the available data on AS and CAD. Herein, we provide an in-depth review of the evidence supporting the decision-making process between transcatheter and surgical approaches and the key elements of treatment selection in patients with AS and CAD.
- 1 November 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 17 (11) , e016683
Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab
BACKGROUND: Elevated Lp(a) (lipoprotein[a]) is a risk marker for atherosclerotic disease, but the underlying mechanisms remain elusive. We examined the association of Lp(a) with changes in coronary atherosclerosis following intensive lipid-lowering therapy. METHODS: In the PACMAN-AMI trial (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction), 300 patients with acute myocardial infarction were randomized to receive biweekly alirocumab 150 mg or placebo in addition to high-intensity statins. Patients underwent serial 2-vessel intravascular ultrasound, optical coherence tomography, and near-infrared spectroscopy in the non–infarct-related arteries at baseline and after 52 weeks. The main end points were percent atheroma volume by intravascular ultrasound, minimum fibrous cap thickness by optical coherence tomography, and maximum lipid core burden index within 4 mm (maxLCBI 4mm ) by near-infrared spectroscopy. RESULTS: A total of 265 patients had serial intravascular ultrasound data (mean age, 58±9 years; 16% women). Alirocumab resulted in greater reductions in percent atheroma volume and maxLCBI 4mm , as well as a greater increase in minimum fibrous cap thickness, compared with placebo. In the alirocumab group, the reduction in maxLCBI 4mm was smaller in patients with higher baseline Lp(a), defined by the highest quartile (Q4, ≥98 nmol/L; n=30), than in those with lower baseline Lp(a) (Q1–Q3, P =0.01 after adjustment for clinically relevant baseline variables), and was comparable to the maxLBI 4mm reduction in the placebo group (−37.60 [−57.40 to −17.80]; n=134). These findings were consistent when higher baseline Lp(a) was defined by cut-off values of ≥75 versus <75 nmol/L (n=35 versus 94, respectively, in the alirocumab group) and ≥125 versus <125 nmol/L (n=23 versus 106, respectively). Changes in percent atheroma volume and minimum fibrous cap thickness did not differ in relation to baseline Lp(a). CONCLUSIONS: In patients with acute myocardial infarction, elevated Lp(a) at baseline is associated with attenuation of plaque lipid regression despite intensive treatment with alirocumab plus high-intensity statin. This finding may explain the residual cardiovascular risk associated with high Lp(a) despite optimal control of lipid levels. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03067844.
- 1 November 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 17 (11) , e016683
Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab
BACKGROUND: Elevated Lp(a) (lipoprotein[a]) is a risk marker for atherosclerotic disease, but the underlying mechanisms remain elusive. We examined the association of Lp(a) with changes in coronary atherosclerosis following intensive lipid-lowering therapy. METHODS: In the PACMAN-AMI trial (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction), 300 patients with acute myocardial infarction were randomized to receive biweekly alirocumab 150 mg or placebo in addition to high-intensity statins. Patients underwent serial 2-vessel intravascular ultrasound, optical coherence tomography, and near-infrared spectroscopy in the non–infarct-related arteries at baseline and after 52 weeks. The main end points were percent atheroma volume by intravascular ultrasound, minimum fibrous cap thickness by optical coherence tomography, and maximum lipid core burden index within 4 mm (maxLCBI 4mm ) by near-infrared spectroscopy. RESULTS: A total of 265 patients had serial intravascular ultrasound data (mean age, 58±9 years; 16% women). Alirocumab resulted in greater reductions in percent atheroma volume and maxLCBI 4mm , as well as a greater increase in minimum fibrous cap thickness, compared with placebo. In the alirocumab group, the reduction in maxLCBI 4mm was smaller in patients with higher baseline Lp(a), defined by the highest quartile (Q4, ≥98 nmol/L; n=30), than in those with lower baseline Lp(a) (Q1–Q3, P =0.01 after adjustment for clinically relevant baseline variables), and was comparable to the maxLBI 4mm reduction in the placebo group (−37.60 [−57.40 to −17.80]; n=134). These findings were consistent when higher baseline Lp(a) was defined by cut-off values of ≥75 versus <75 nmol/L (n=35 versus 94, respectively, in the alirocumab group) and ≥125 versus <125 nmol/L (n=23 versus 106, respectively). Changes in percent atheroma volume and minimum fibrous cap thickness did not differ in relation to baseline Lp(a). CONCLUSIONS: In patients with acute myocardial infarction, elevated Lp(a) at baseline is associated with attenuation of plaque lipid regression despite intensive treatment with alirocumab plus high-intensity statin. This finding may explain the residual cardiovascular risk associated with high Lp(a) despite optimal control of lipid levels. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03067844.
- Open Access
- 1 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (29) , 2906-2916
Long-term effect of biodegradable vs. durable polymer everolimus-eluting stents on neoatherosclerosis in ST-segment elevation myocardial infarction: the CONNECT trial
Background and Aims: Neoatherosclerosis is a leading cause of late (>1 year) stent failure following drug-eluting stent implantation. The role of biodegradable (BP) vs. durable polymer (DP) drug-eluting stents on long-term occurrence of neoatherosclerosis remains unclear. Superiority of biodegradable against durable polymer current generation thin-strut everolimus-eluting stent (EES) was tested by assessing the frequency of neoatherosclerosis 3 years after primary percutaneous coronary intervention (pPCI) among patients with ST-segment elevation myocardial infarction (STEMI). Methods: The randomized controlled, multicentre (Japan and Switzerland) CONNECT trial (NCT03440801) randomly (1:1) assigned 239 STEMI patients to pPCI with BP-EES or DP-EES. The primary endpoint was the frequency of neoatherosclerosis assessed by optical coherence tomography (OCT) at 3 years. Neoatherosclerosis was defined as fibroatheroma or fibrocalcific plaque or macrophage accumulation within the neointima. Results: Among 239 STEMI patients randomized, 236 received pPCI with stent implantation (119 BP-EES; 117 DP-EES). A total of 178 patients (75%; 88 in the BP-EES group and 90 in the DP-EES group) underwent OCT assessment at 3 years. Neoatherosclerosis did not differ between the BP-EES (11.4%) and DP-EES (13.3%; odds ratio 0.83, 95% confidence interval 0.33–2.04, P = .69). There were no differences in the frequency of fibroatheroma (BP-EES 9.1% vs. DP-EES 11.1%, P = .66) or macrophage accumulation (BP-EES 4.5% vs. DP-EES 3.3%, P = .68), and no fibrocalcific neoatherosclerosis was observed. Rates of target lesion failure did not differ between groups (BP-EES 5.9% vs. DP-EES 6.0%, P = .97). Conclusions: The use of BP-EES for primary PCI in patients presenting with STEMI was not superior to DP-EES regarding frequency of neoatherosclerosis at 3 years.
- 1 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (29) , 2906-2916
Open AccessLong-term effect of biodegradable vs. durable polymer everolimus-eluting stents on neoatherosclerosis in ST-segment elevation myocardial infarction: the CONNECT trial
Background and Aims: Neoatherosclerosis is a leading cause of late (>1 year) stent failure following drug-eluting stent implantation. The role of biodegradable (BP) vs. durable polymer (DP) drug-eluting stents on long-term occurrence of neoatherosclerosis remains unclear. Superiority of biodegradable against durable polymer current generation thin-strut everolimus-eluting stent (EES) was tested by assessing the frequency of neoatherosclerosis 3 years after primary percutaneous coronary intervention (pPCI) among patients with ST-segment elevation myocardial infarction (STEMI). Methods: The randomized controlled, multicentre (Japan and Switzerland) CONNECT trial (NCT03440801) randomly (1:1) assigned 239 STEMI patients to pPCI with BP-EES or DP-EES. The primary endpoint was the frequency of neoatherosclerosis assessed by optical coherence tomography (OCT) at 3 years. Neoatherosclerosis was defined as fibroatheroma or fibrocalcific plaque or macrophage accumulation within the neointima. Results: Among 239 STEMI patients randomized, 236 received pPCI with stent implantation (119 BP-EES; 117 DP-EES). A total of 178 patients (75%; 88 in the BP-EES group and 90 in the DP-EES group) underwent OCT assessment at 3 years. Neoatherosclerosis did not differ between the BP-EES (11.4%) and DP-EES (13.3%; odds ratio 0.83, 95% confidence interval 0.33–2.04, P = .69). There were no differences in the frequency of fibroatheroma (BP-EES 9.1% vs. DP-EES 11.1%, P = .66) or macrophage accumulation (BP-EES 4.5% vs. DP-EES 3.3%, P = .68), and no fibrocalcific neoatherosclerosis was observed. Rates of target lesion failure did not differ between groups (BP-EES 5.9% vs. DP-EES 6.0%, P = .97). Conclusions: The use of BP-EES for primary PCI in patients presenting with STEMI was not superior to DP-EES regarding frequency of neoatherosclerosis at 3 years.
- Open Access
- 26 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1322
Total Muscle Area and Visceral Adipose Tissue Measurements for Frailty Assessment in TAVR Patients
Background: Transcatheter aortic valve replacement (TAVR) is a treatment option for severe aortic valve stenosis. Pre-TAVR assessments, extending beyond anatomy, include evaluating frailty. Potential frailty parameters in pre-TAVR computed tomography (CT) scans are not fully explored but could contribute to a comprehensive frailty assessment. The primary objective was to investigate the impact of total muscle area (TMA) and visceral adipose tissue (VAT) as frailty parameters on 5-year all-cause mortality in patients undergoing TAVR. Methods: Between 01/2017 and 12/2018, consecutive TAVR patients undergoing CT scans enabling TMA and VAT measurements were included. Results: A total of 500 patients qualified for combined TMA and VAT analysis. Age was not associated with a higher risk of 5-year mortality (HR 1.02, 95% CI: 0.998–1.049; p = 0.069). Body surface area normalized TMA (nTMA) was significantly associated with 5-year, all-cause mortality (HR 0.927, 95% CI: 0.927–0.997; p = 0.033), while VAT had no effect (HR 1.002, 95% CI: 0.99–1.015; p = 0.7). The effect of nTMA on 5-year, all-cause mortality was gender dependent: the protective effect of higher nTMA was found in male patients (pinteraction: sex × nTMA = 0.007). Conclusions: Normalized total muscle area derived from a routine CT scan before transcatheter aortic valve replacement complements frailty assessment in patients undergoing TAVR.
- 26 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1322
Open AccessTotal Muscle Area and Visceral Adipose Tissue Measurements for Frailty Assessment in TAVR Patients
Background: Transcatheter aortic valve replacement (TAVR) is a treatment option for severe aortic valve stenosis. Pre-TAVR assessments, extending beyond anatomy, include evaluating frailty. Potential frailty parameters in pre-TAVR computed tomography (CT) scans are not fully explored but could contribute to a comprehensive frailty assessment. The primary objective was to investigate the impact of total muscle area (TMA) and visceral adipose tissue (VAT) as frailty parameters on 5-year all-cause mortality in patients undergoing TAVR. Methods: Between 01/2017 and 12/2018, consecutive TAVR patients undergoing CT scans enabling TMA and VAT measurements were included. Results: A total of 500 patients qualified for combined TMA and VAT analysis. Age was not associated with a higher risk of 5-year mortality (HR 1.02, 95% CI: 0.998–1.049; p = 0.069). Body surface area normalized TMA (nTMA) was significantly associated with 5-year, all-cause mortality (HR 0.927, 95% CI: 0.927–0.997; p = 0.033), while VAT had no effect (HR 1.002, 95% CI: 0.99–1.015; p = 0.7). The effect of nTMA on 5-year, all-cause mortality was gender dependent: the protective effect of higher nTMA was found in male patients (pinteraction: sex × nTMA = 0.007). Conclusions: Normalized total muscle area derived from a routine CT scan before transcatheter aortic valve replacement complements frailty assessment in patients undergoing TAVR.